Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Clinical trial NCT06361589 · RECRUITING

Trial details

NCT number: NCT06361589
Sponsor: Sichuan Cancer Hospital and Research Institute
Status: RECRUITING
Study type: OBSERVATIONAL

ALK-positive Non-small Cell Lung Cancer Real World Study

Start date: 2024-05-01
Primary completion: 2026-11-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.